Table 2.

Main outcomes with Dabigatran vs. Warfarin in Asians in RE-LY trial.

	Dabigatran 110 mg (N = 923)	Dabigatran 150 mg (N = 933)	Warfarin (N = 926)	Dabigatran 110 mg vs. Warfarin	Dabigatran 150 mg vs. Warfarin
	%/y	%/y	%/y	HR (95% CI)	HR (95% CI)
Stroke or SE	2.50	1.39	3.06	0.81 (0.54–1.21)	0.45 (0.28–0.72)
Major bleeding	2.22	2.17	3.82	0.57 (0.39–0.85)	0.57 (0.38–0.84)
Myocardial infarction	0.51	0.50	0.58	0.88 (0.36–2.17)	0.87 (0.35–2.13)
Gastrointestinal major bleeding	1.15	0.96	1.41	0.82 (0.45–1.49)	0.69 (0.37–1.27)